Kornimate/medical-research-clean huggingface dataset:
comparison of hip resurfacing to large femoral head total hip arthroplasty

Conditions: Osteoarthritis; Avascular Necrosis

Summary: this study evaluates femoral head resurfacing versus a large femoral head (durom®) total hip system. this is a prospective randomized trial.


Eligibility criteria:
inclusion criteria: 1. indication for hip resurfacing because of osteoarthritis or avascular necrosis 2. aged 19 to 65 years old 3. ability to give informed consent exclusion criteria: 1. previous fracture requiring internal fixation of the hip 2. previous hip osteotomy (pelvic or femoral) 3. dysplasia requiring structural bone graft 4. inability to respond to questionnaires in english (or french, montreal centre only) 5. the presence of osteopenia or osteoporosis 6. evidence of hepatic/renal insufficiency or failure from medical history or laboratory assessment

Keywords: osteoarthritis/avascular necrosis hip
sentinel lymph nodes biopsy in cervical cancer

Conditions: Sentinel Lymph Node

Summary: this study aims to compare sentinel lymph nodes biopsy versus comprehensive lymphadenectomy in patients with early stage cervical cancer who underwent radical hysterectomy.


Eligibility criteria:
inclusion criteria: women aged 20 and above with clinical figo stage i-iia cervical cancer exclusion criteria: women did not receive surgical treatment
identify genetic variations that affect the ability of patients to metabolize drugs through metabolic pathways

Conditions: Chronic Disease; Endocrine System Disease; Cardiovascular Disease; Respiratory Tract Disease; CNS Metabolic Disorders

Summary: this observation will look at patient care decisions of the primary healthcare provider utilizing the results of the dna testing of patients' metabolic pathways using 2c19, 2c9, 2d6, 3a4, factor ii, factor v and mthfr and vkorc1. findings of the data collection will be published to optimize the benefits of pharmacogenomics testing and publish health outcomes.

this study will analyze de-identified data from patients identified by the primary healthcare provider where a dna sample has been collected; the medical history and medications at the time the dna sample was collected; the date of the dna pathway testing and the results. the study will collect and assess the patient data where the healthcare provider has explained the results of the dna testing to the patient and made applicable changes in the healthcare plan based on the dna pathway results. patients will have returned to the healthcare provider after a minimum of ninety (90) days for follow-up to assess the outcome of the care plan changes started after the dna results provided. this study will collect the healthcare provider will provide the outcomes of the healthcare plan changes.

Eligibility criteria:
inclusion criteria: 1. adult male or female patients age 18 or older 2. prescribed at least one medication with in any of the metabolic pathways being assessed will be enrolled in the study. 3. completed dna testing for the pathways under review for this observation. exclusion criteria: 1. anticipated life expectancy less than 1 month. 2. employee of the investigator, with direct involvement in the proposed study or other studies under the direction of the investigator, as well as immediate family members or the employee or primary care provider.
combination chemotherapy given with radiation therapy or radiation therapy alone in treating patients with early-stage hodgkin's disease

Conditions: Lymphoma

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining radiation therapy with chemotherapy may kill more tumor cells. purpose: randomized phase iii trial to compare the effectiveness of combination chemotherapy plus radiation therapy with radiation therapy alone in treating patients with early-stage hodgkin's disease.

objectives: i. determine the recurrence rate and long term survival of patients with early stage hodgkin's disease given vincristine/doxorubicin/prednisolone/ etoposide/cyclophosphamide/bleomycin (vapec-b) chemotherapy and involved field radiation vs mantle radiotherapy. outline: this is a randomized multicenter study. patients are randomized to receive either vincristine/doxorubicin/prednisolone/etoposide/cyclophosphamide/ bleomycin (vapec-b) chemotherapy and involved field radiotherapy or mantle radiotherapy only. patients receiving vapec-b are given prednisolone daily on weeks 1-6, doxorubicin iv along with cyclophosphamide iv on week 1, doxorubicin iv and etoposide orally for 5 days on week 3, and vincristine and bleomycin iv on weeks 2 and 4. involved field radiotherapy is commenced at week 6, within 14 to 21 days of the last chemotherapy treatment. patients randomized to receive mantle radiotherapy only are given treatments daily for 4 weeks. patients are followed every 3 months for the first two years, every 4 months for the third year, every 6 months for the fourth and fifth years and annually thereafter. projected accrual: 400 patients will be accrued over 4-5 years.

Eligibility criteria:
disease characteristics: histologically proven stage ia or iia hodgkin's disease without mediastinal bulk patients with hodgkin's disease existing below diaphragm only are not eligible patient characteristics: age: 16 to 75 performance status: not specified life expectancy: not specified hematopoietic: not specified hepatic: not specified renal: not specified other: not hiv positive no prior malignancy other than basal cell carcinoma or cervical intraepithelial neoplasia prior concurrent therapy: no prior treatment

Keywords: stage i adult hodgkin lymphoma stage ii adult hodgkin lymphoma
longitudinal outcomes in pediatric rtms and cit

Conditions: Congenital Hemiparesis

Summary: track behavioral and qualitative longitudinal outcomes in children with hemiparesis who previously participated in a randomized, controlled trial (rct) of intensive therapy combined with repetitive transcranial magnetic stimulation (rtms)

this longitudinal study will evaluate the subjective and behavioral outcomes of a previous randomized controlled study (rct) rtms/cit (pediatric hemiparesis: synergistic treatment using rtms and cit (nih grant number: 1rc1hd063838-01; pi: dr. james carey). the previous rtms/cit study evaluated the safety and efficacy of 5 treatments of 6-hz primed low-frequency rtms applied to the non-stroke hemisphere combined with constraint induced therapy (cit) to promote recovery of the paretic hand in children and adolescents. cit has shown improved behavioral outcomes as well as cortical reorganization in representation of the affected limb. the previous rct was a rtms-sham/cit study design (real rtms n=10 and sham rtms n=9). our research question, 'what is the medical status and perception of previous participants concerning their involvement in an intensive rtms/cit rct specific to symptom monitoring, the tms experience, and their current functional status'.

Eligibility criteria:
inclusion criteria: * previous participants in a rct on rtms/cit. exclusion criteria: * participants who do not wish to participate.
coordinated vaccination against rsv and influenza in patients with chronic heart failure and its impact on prognosis.

Conditions: Heart Failure; RSV Infection; Influenza; Vaccines

Summary: this prospective, single-centre, open-label, randomized study aims to determine whether coordinated care in administering protective vaccinations (against respiratory syncytial virus (rsv) and influenza) impacts the prognosis of patients with chronic heart failure. the main question it aims to answer is: • does coordinated care through vaccinations improve the prognosis of patients with chronic heart failure?

the study aims to determine whether coordinated care in the form of administering protective vaccinations affects the prognosis of patients with chronic heart failure. the study will involve analyzing epidemiological data for each participant, followed by randomization into two treatment paths: receiving vaccinations against respiratory syncytial virus (rsv) and influenza provided by the research team (i.e., during cardiology visits) versus following standard recommendations for protective vaccinations (i.e., receiving vaccinations at vaccination points). all vaccinations will be administered using vaccines registered with the appropriate authorities and approved for use in the eu and poland.

Eligibility criteria:
inclusion criteria: * age above 18 years * willingness to provide informed consent for participation in the study * diagnosis of heart failure * no previous vaccination against rsv or influenza exclusion criteria: * history of an anaphylactic reaction to vaccination * hypersensitivity to any component of the vaccine * receipt of vaccination against rsv or influenza in the current infectious * active infection * pregnancy

Keywords: heart failure rsv influenza vaccination immunization prognosis
the effectiveness of a smartphone application in the treatment of alcohol use disorder

Conditions: Alcohol Use Disorder

Summary: alcohol dependence poses a major problem for irish and uk society, placing a huge burden on the health system. it is difficult to treat and relapse is common. there is an urgent need to develop novel treatment methods. one growing area of intervention is the use of mobile phone technology to develop personalised, patient-centred treatments. these can be used in outpatient settings, allowing patients to manage their own illness and take control of their recovery. in this study the investigators will investigate how a smartphone application, ucontroldrink, can help alcoholics stay abstinent from alcohol. the application consists of a number of features known to aid recovery such as supportive messages and online therapy.

alcohol use disorder (aud) is a common and difficult disorder to treat. only a fraction of sufferers seek treatment and the rate of relapse is high. there is therefore an urgent need for improved methods of promoting long term abstinence and recovery in aud. this study will explore the effectiveness of a smartphone application, ucontroldrink, in aiding recovery from aud in patients who have been discharged from an inpatient alcohol treatment programme. the application comprises five recovery focused features: supportive messages, computerised-cognitive behavioural therapy, a drinking log, activities and trigger avoidance log, craving management and gamification. patients will use the application for 3 months. a control group of patients will also be followed over the same time period. cumulative abstinence duration as well as changes in questionnaire measures to baseline, time to first drink, proportion of patients continuously abstinent from alcohol, levels of activity within the app and patient satisfaction with their overall treatment will be measured at 3 months. if successful, this application may offer a unique, patient-centred, technology-driven, cost effective method of improving outcomes in aud.

Eligibility criteria:
inclusion criteria: 1. patients will fulfil the criteria for an alcohol use disorder according to the structured clinical interview for dsm-5 axis i disorders 2. patients must complete an alcohol treatment programme at st. patrick's university hospital. 3. primary addiction must be alcohol in poly-substance abusers. 4. aged over 18 years of age and capable of providing written, informed consent. 5. mini mental state examination (msse) score of ≥25. 6. patients must have an iphone or android smartphone and are familiar with using smartphone applications. exclusion criteria: 1. patients whose primary substance of abuse is not alcohol, although may meet the criteria for alcohol dependency/abuse. 2. patients who do not have an iphone or android smartphone. 3. age \ 70years. 4. psychotic disorder 5. patients who do not fully complete an inpatient treatment programme before discharge. 6. history of alcohol use disorder but not current.

Keywords: alcohol use disorder smartphone application
study of dextromethorphan in ocd and related disorders

Conditions: Obsessive-Compulsive Disorder; Illness Anxiety Disorder; Body Dysmorphic Disorders; Somatic Symptom Disorder

Summary: the purpose of the study is to assess the tolerability and efficacy of dextromethorphan in combination with fluoxetine for symptom relief in ocd and related disorders.

obsessive compulsive disorder (ocd) and the related disorders body dysmorphic disorder (bdd), somatic symptom disorder (ssd) and illness anxiety disorder (iad) are psychiatric conditions characterized by recurrent, intrusive thoughts, feelings or images (obsessions or preoccupations) and repetitive or ritualized behaviors or avoidance performed to relieve obsession or preoccupation-related anxiety. they are a significant cause of mental health-related disability, and are inadequately served by available treatments. this study tests whether an over-the-counter cough suppressant medicine, dextromethorphan, may offer symptom relief when combined with a low dose of fluoxetine, a standard prescription treatment for ocd and related disorders.

Eligibility criteria:
inclusion criteria: * diagnosis of obsessive-compulsive disorder (ocd), body dysmorphic disorder (bdd), illness anxiety disorder (iad) or somatic symptom disorder (ssd) * living within california * capacity to provide informed consent exclusion criteria: * current bipolar disorder or psychotic disorder * active moderate or severe substance use disorder, lifetime severe substance use disorder * pregnant or nursing women * use of prescribed psychotropic medications other than fluoxetine for 2 weeks prior to study start * having commenced ocd-targeted exposure and response-prevention (exrp) psychotherapy within 2 months of study start

Keywords: ocd bdd iad ssd fluoxetine dextromethorphan
stem cell and conditioned medium for cerebral palsy

Conditions: Cerebral Palsy

Summary: the aim of this study was to compare the effectiveness of umbilical cord mesenchymal stem cells (ucmscs) and conditioned medium (cm) administration, ucmscs only and control with standard therapy. hypothesis: ucmscs + cm therapy resulting in higher improvement in cognitive function, gross motor function and chemical factors than ucmscs and standard therapy.


Eligibility criteria:
inclusion criteria: * diagnosed as cerebral palsy with total body involvement type * age between 6 month - 3 years old * parents requesting for cell therapy * the parents give sign in informed consent form do to examination, therapy, blood sampling collection and observation for their child exclusion criteria: * head circumference less than -3 sd (more than 3 cm) nellhaus standard * have diagnosed meningitis and encephalitis * have diagnosed congenital infection i.e. toxoplasmosis, rubella congenital, cytomegalovirus * have diagnosed metabolic disorder, chromosome disorder, congenital malformation or neuroregeneratif disease * progressive disorder * regressive development disorder * severe anatomical abnormalities in brain mri

Keywords: allogeneic mesenchymal stem cells umbilical cord mesenchymal stem cells intrathecal injection cerebral palsy conditioned medium
validation of the 3d-cam and the ub-cam in french

Conditions: Delirium

Summary: delirium is very common in hospitalized older patients and associated with serious clinical bad outcomes (e.g. increased risk of functional decline and death). despite its high prevalence in the hospital setting, delirium remains underdiagnosed. a better identification would allow an early management and a reduction of its complications. the validation of easy-to-use and quick and formalized tools for the identification of delirium and their implementation in the clinical practice are necessary. recently, the 3d-cam (3-minutes diagnostic interview for confusion assessment method -defined delirium) and the ub-cam (ultra-brief cam) showed very high sensitivity and specificity (\> 90%), compared to the reference standard (diagnostic and statistical manual of mental disorders (dsm criteria)) for the diagnosis of delirium. the investigators aimed to evaluate the sensitivity and specificity of the french versions of the 3d-cam and the ub-cam used in delirium screening in older adults hospitalized in geriatric units, compared to reference standard.


Eligibility criteria:
inclusion criteria: * adults hospitalized in acute geriatric units * aged 65 or older * patient (or relative) not objecting to participating in the study exclusion criteria: - legal protection regimes (guardianship, curatorship)

Keywords: delirium cam ub-cam 3d-cam
low intensity focused ultrasound for binge eating disorder

Conditions: Binge-Eating Disorder

Summary: this study is a prospective, single-center, single-arm early feasibility study, to establish safety and tolerability of lifu for neuromodulation in patients with binge eating disorder (bed)

the primary objective is to evaluate the safety, feasibility and tolerability of lifu as an adjunct neuromodulatory treatment for bed

Eligibility criteria:
inclusion criteria: * males and non-pregnant females, 22 - 65 years of age. * participant meets dsm-5 criteria for moderate to extreme bed. * weight ≤450lb to accommodate in mri. * shoulder width of ≤65 inches to accommodate in mri. * the neuromodulation targets are visible on mri for target selection. * participant is able and willing to give informed consent. exclusion criteria: * unable to undergo mr-imaging because of implanted pacemakers, medication pumps, aneurysm clips, metallic prostheses (including metal pins and rods, heart valves or cochlear implants), shrapnel fragments, permanent make-up or small metal fragments in the eye that welders and other metal workers may have, or if candidates are uncomfortable in small spaces (have claustrophobia). * participants with more than 30% of the skull area traversed by the sonication pathway are covered by scars, scalp disorders (e.g., eczema), atrophy of the scalp, or implanted objects in the skull or the brain. * participants with known untreated or unstable cardiac status or hypertension * evidence of substance (alcohol or other drug) use disorder during the previous 12 months (assessed via scid-5). * past or present diagnosis of schizophrenia, psychotic disorder or bipolar disorder (assessed via scid-5) * participant who is currently participating in another clinical investigation with an active treatment arm. * use of any medications that, in the opinion of the investigator, may put the participant at higher risk for aes, or impair the participant's ability to perform complete study procedures. * participant is considered to be a poor surgical or study candidate, which may include, but is not limited to the following: any medical, social, or psychological problem that could complicate the required procedures and evaluations of the study in the judgment of the investigator. * participant is pregnant/lactating or planning to be pregnant.
effect of 2% lignocaine solution in pain during removal of nasal pack

Conditions: Nasal Pack Removal

Summary: to evaluate the efficacy of rehydration of merocel nasal packs with 2% lignocaine on reducing pain and discomfort during nasal pack removal in patients undergoing septoplasty.

this study will be carried out in patients who have undergone septoplasty for deviated nasal septum under general anesthesia, and who are categorized as american society of anesthesiologists (asa) grade i to ii. consent will be obtained from the patient for the same. septoplasty will be carried out under general anesthesia and in all patients merocel nasal packs (expandable polyvinyl acetate nasal packing) that expand upon contact with fluid will be used. the postoperative analgesia will include ibuprofen 400mg + paracetamol 500mg combination thrice daily and ketorolac 30mg intravenous when needed. the packs will be removed on the second postoperative day, 48 hours after packing. during nasal pack removal, the subjects will be randomly divided into 2 groups: the lignocaine group (2% lignocaine hcl) and the normal saline group (0.9% nacl) using simple random sampling by lottery method. subjects won't know which group they belong to and what medication they will be receiving. a 23-gauge needle will be used for direct application of the treatment to the merocel, with care taken not to touch the patient. in the lignocaine group, 2.5 ml of 2% of lignocaine is diluted with 2.5 ml of distilled water, and the 5ml solution will be injected into the merocel pack 15 minutes before removal of the pack. nothing will be done to the opposite nostril, which would act as a control. in the normal saline group, 5 ml of normal saline was injected into the merocel pack 15 minutes before removal of the pack. nothing will be done to the opposite nostril. all patients will be blinded to which group they belong and which solution was being kept in their pack. all patients will be asked to evaluate the severity of pain during removal of nasal packing by visual analogue scale (vas) (range, 0-10; 0 = no pain and 10 = intolerable pain). adverse events such as vomiting and nausea will be recorded. these procedures will be done by the same team to minimize observer variations.

Eligibility criteria:
inclusion criteria: * symptomatic deviated nasal septum undergone septoplasty surgery with bilateral anterior nasal packing exclusion criteria: * history of previous nasal surgeries * nasal polyposis * allergic rhinitis * chronic sinusitis * patient with neurological and psychiatric disease * patient with sensitivity to anesthetic agent in study * patients unwilling to enroll in the study

Keywords: anterior nasal pack nasal pack removal 2% lignocaine